Alector Price Target Raised to $8 Following Strategic Licensing Deal with Roche

Key Facts

1H.C. Wainwright raised its price target for Alector from $5.00 to $8.00 while maintaining a Buy rating.

2Alector signed a licensing agreement with Roche's Genentech, including a $100 million upfront payment.

3The company's financial runway is now extended into 2029 thanks to the new strategic agreement.

H.C. Wainwright raised its price target for Alector from $5.00 to $8.00 while maintaining a Buy rating. The upgrade follows the company signing a licensing agreement with Roche's Genentech, which includes a $100 million upfront payment and potential milestone payments of up to $1.17 billion.

ALEC closed at $1.87 on October 13, 2026, while Roche's RHHVF closed at $438.07 on the same date. According to Financial Modeling Prep, this strategic agreement extends Alector's financial runway into 2029, supporting the continued development of its Brain Carrier platform and neurodegenerative disease pipeline.